PHARMACOGENETICS OF DIABETES PREVENTION

预防糖尿病的药物遗传学

• 批准号: 7716715
• 负责人: RICHARD M WATANABE
• 金额: $ 0.96万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716715
• 关键词: Accounting; Blood specimen; Computer Retrieval of Information on Scientific Projects Database; Diabetes prevention; Dose; Drug Kinetics; Funding; Gestational Diabetes; Grant; Institution; Kinetics; Mexican Americans; Pharmacogenetics; Pioglitazone; Research; Research Design; Research Personnel; Resources; Source; United States National Institutes of Health; Woman; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. These studies are designed to assess potential differences in the pharmacokinetics of pioglitazone in Mexican American women with previous gestational diabetes. Women who previously participated in the "Pioglitazone in the Prevention of Diabetes" trial and whose response to pioglitazone is known will be invited to participate in this study. Ten responders and 10 non-responders will be administered a single 45 mg pioglitazone dose and blood samples will be collected over a 24 hr period to assess kinetics of pioglitazone and its metabolites. The results will determine whether response to pioglitazone is accounted for by differences in pharmacokinetics.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这些研究旨在评估既往患有妊娠糖尿病的墨西哥裔美国女性中吡格列酮药代动力学的潜在差异。 将邀请既往参加过“吡格列酮预防糖尿病”试验且已知吡格列酮应答的女性参加本研究。 10名应答者和10名非应答者将接受45 mg吡格列酮单次给药，并在24小时内采集血样，以评估吡格列酮及其代谢产物的动力学。 结果将确定吡格列酮的反应是否由药代动力学差异引起。